<DOC>
	<DOCNO>NCT00002981</DOCNO>
	<brief_summary>RATIONALE : New image procedure , PET scan , may improve ability detect new recurrent prostate cancer .</brief_summary>
	<brief_title>PET Scan Treating Patients With Metastatic Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Measure pharmacokinetics , whole body retention isotope , biodistribution C11-methionine FDG PET image serial sample blood men progressive prostate cancer . - Explore metabolism PET scan compare sensitivity C11-methionine FDG PET scan androgen independent prostate cancer metastases sensitivity C11-methionine FDG androgen dependent metastases site site basis . - Compare C11-methionine FDG PET scan standard care diagnostic study include Tc 99m bone scan , computed tomography , magnetic resonance imaging . Patients fast 6 hour prior PET image exception liberal water intake encourage . A two way catheter place urinary bladder , continuous isotonic saline irrigation perform throughout scan acquisition reduce interference image lesion pelvic lymph node adjacent pelvic bone cause radiation excrete urine hold bladder . Each patient receive C11-methionine intravenously . PET image begin immediately injection approximately 60 minute total use standard imaging procedure . Immediately follow completion image C11-methionine administration , patient receives FDG intravenously . PET image begin approximately 45 minute thereafter approximately 60 minute use standard imaging procedure .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Carbon-11 methionine</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm prostate adenocarcinoma Must least 50 % increase PSA sustain minimum 3 observation obtain least 1 week apart Must development new lesion bone scintigraphy great 50 % increase measurable disease CT MRI scan Metastatic disease PATIENT CHARACTERISTICS : Age : Not specify Performance status : Karnofsky great 60 % Hematopoietic : ANC great 1,000/mm^3 Platelet count great 100,000/mm^3 Hepatic : Not specify Renal : Not specify Cardiovascular : No clinically significant cardiac disease Pulmonary : No clinically significant pulmonary disease Other : No active infection control antibiotic PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>